0% 10% 20% 30% 40% 50% 1 2 3 4 5 6 7 8 9 10 11 Tarcocimab BRVO Tarcocimab All RVO Aflibercept BRVO Aflibercept All RVO Number of injections through Year 1 Proportion of subjects 78% received ≤5 doses with tarcocimab 93% received ≥ 6 doses with aflibercept Tarcocimab demonstrated high efficacy and industry-leading durability in Retinal Vein Occlusion in the Phase 3 BEACON study 31 RVO BEACON RVO: retinal vein occlusion; BRVO: branched retinal vein occlusion; 1. Durability interval calculated based on patients that received no injections (46%) or 1 injection (29%) over the second 6 months of Year 1. 2. RVO market size from imarc: RVO Market Size, Epidemiology, In-Market drug sales, pipeline therapies, and Regional Outlook Tarcocimab: Number of doses in the second 6 months of Year 1 0-1 doses 2 doses 18% 4-6 doses: 2% 3 doses: 5% 6-month durability 75% 1 RVO is a ~$3 billion market. Gen 1.5 agents have failed to address the key unmet need for high efficacy with better durability. Tarcocimab delivered 6-month durability in 75% of patients in BEACON and is uniquely poised to be a valuable medicine in this market Quadrant of core unmet need Primary endpoint 6-month durability